Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
Details
Publication Year 2024-06,Volume 30,Issue #4,Page 642-660
Journal Title
Journal of Oncology Pharmacy Practice
Publication Type
Research article
Abstract
BACKGROUND: Investigation of infection risk with subcutaneous versus intravenous trastuzumab and rituximab administration in an individual patient data (IPD) and published data meta-analysis of randomised controlled trials (RCTs). METHODS: Databases were searched to September 2021. Primary outcomes were serious and high-grade infection. Relative-risk (RR) and 95% confidence intervals (95%CI) were calculated using random-effects models. RESULTS: IPD meta-analysis (6 RCTs, 2971 participants, 2320 infections) demonstrated higher infection incidence with subcutaneous versus intravenous administration, without reaching statistical significance (serious: 12.2% versus 9.3%, RR 1.28, 95%CI 0.93to1.77, P = 0.13; high-grade: 12.2% versus 9.9%, RR 1.32, 95%CI 0.98to1.77, P = 0.07). With exclusion of an outlying study in post-hoc analysis, increased risks were statistically significant (serious: 13.1% versus 8.4%, RR 1.53, 95%CI 1.14to2.06, P = 0.01; high-grade: 13.2% versus 9.3%, RR 1.56, 95%CI 1.16to2.11, P < 0.01). Published data meta-analysis (8 RCTs, 3745 participants, 648 infections) demonstrated higher incidence of serious (HR 1.31, 95%CI 1.02to1.68, P = 0.04) and high-grade (HR 1.52, 95%CI 1.17to1.98, P < 0.01) infection with subcutaneous versus intravenous administration. CONCLUSIONS: Results suggest increased infection risk with subcutaneous versus intravenous administration, although IPD findings are sensitive to exclusion of one trial with inconsistent results and identified risk-of-bias. Ongoing trials may confirm findings. Clinical surveillance should be considered when switching to subcutaneous administration. PROSPERO registration CRD42020221866/CRD42020125376.
Publisher
Sage
Keywords
Humans; *Rituximab/administration & dosage/adverse effects; *Trastuzumab/administration & dosage/adverse effects; Injections, Subcutaneous; *Administration, Intravenous; Antineoplastic Agents, Immunological/administration & dosage/adverse effects; Infections/epidemiology; Randomized Controlled Trials as Topic; Neoplasms/drug therapy; Incidence; Monoclonal antibody; infection; rituximab; subcutaneous; trastuzuamb
Department(s)
Pharmacy; Medical Oncology; Clinical Haematology; Infectious Diseases
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-06-25 08:02:22
Last Modified: 2024-06-25 08:02:45

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙